Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
Betsy Goodfellow | November 23, 2023 | News story | Medical Communications | Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b trial for patients with ulcerative colitis (UC), having published this data in the Journal of Crohn’s and Colitis.
The trial included 38 patients, with the patients randomised to either receive various doses of the NX-13 or a placebo. NX-13 was well-tolerated in all patients, with no deaths or severe adverse events reported, and only mild to moderate adverse events being observed.
Most patients who received the drug for four weeks showed consistent and rapid clinical improvement in total Mayo score and in symptomatic relief. Endoscopic improvement was observed to correlate closely with symptom improvement.
The drug is now being assessed in the NEXUS trial – a randomised, multi-centre, double-blind, placebo-controlled, multiple dose, statistically powered, phase 2 proof-of-concept study. Results are expected in the fourth quarter of 2024.
Bram Verstockt MD PhD, lead author on the publication, commented: “Despite advances in UC treatments, the need for new and novel therapies such as NX-13 remains highly important for patients. The early signs of efficacy, along with a favorable safety profile, highlighted in this publication are encouraging. I am excited about the potential of NX-13 and immunometabolism in breaking the inflammatory cycle in UC, which remains a significant unmet need in effectively treating patients.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
